Boehringer plans to cut thousands of jobs<\/a><\/p>\n <\/p>\n
<\/p>\n
<\/p>","protected":false},"excerpt":{"rendered":"
A causa delle rettifiche di bilancio made \u200b\u200bin USA nonch\u00e9 misure di contenimento dei costi nei paesi europei Venerd\u00ec 26 settembre, 2014 \/ El Global Secondo le informazioni raccolte dall’agenzia Reuters e dal portale specializzato Pharma Times, la casa farmaceutica tedesca Boehringer Ingelheim ha annunciato la propria intenzione di dichiarare un totale di 600 esuberi …<\/p>","protected":false},"author":4,"featured_media":806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[27],"class_list":["post-3617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-primo-piano","tag-licenziati"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/3617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=3617"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/3617\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/806"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=3617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=3617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=3617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/www.boehringer-ingelheim.com\/content\/dam\/internet\/opu\/com_EN\/images_new\/01_news\/Image_gallery\/management\/Andreas_Barner_2014_pv.jpg\")
According to the information collected by the Reuters agency and the specialized portal Pharma Times<\/a>, the German pharmaceutical company Boehringer Ingelheim<\/a> announced its intention to make a total of 600 redundancies in Germany. To justify this decision, the company allegedly appealed to budget adjustments made in the USA (its largest market with over 5,000 million euros in revenues in 2013), as well as cost-containment measures in European countries. These measures, together with the loss of some patents and currency effects led to almost 4 percent of the German company's sales decline in 2013.<\/p>\n